Activated platelets rescue apoptotic cells via paracrine activation of EGFR and DNA-dependent protein kinase

Cell Death and Disease

Volumn 5, Issue 9, 2014, Pages

  Au, A E L ^a   Sashindranath, M ^a   Borg, R J ^a   Kleifeld, O ^a   Andrews, R K ^a   Gardiner, E E ^a   Medcalf, R L ^a   Samson, A L ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

DNA DEPENDENT PROTEIN KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ETOPOSIDE;

ACQUIRED BRAIN INJURY; ANIMAL CELL; APOPTOSIS; ARTICLE; CANCER CELL; CONTROLLED STUDY; HEMOSTASIS; HUMAN; HUMAN CELL; IN VITRO STUDY; MOUSE; NERVOUS SYSTEM INJURY; NEUROPROTECTION; NONHUMAN; PARACRINE SIGNALING; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; ADOLESCENT; ADULT; AGED; ANIMAL; BRAIN; BRAIN INJURY; C57BL MOUSE; CELL CULTURE; CYTOLOGY; ENZYMOLOGY; FEMALE; GENETICS; MALE; METABOLISM; MIDDLE AGED; NERVE CELL; PATHOPHYSIOLOGY; TUMOR CELL LINE; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANIMALS; APOPTOSIS; BLOOD PLATELETS; BRAIN; BRAIN INJURIES; CELL LINE, TUMOR; CELLS, CULTURED; DNA-ACTIVATED PROTEIN KINASE; FEMALE; HUMANS; MALE; MICE, INBRED C57BL; MIDDLE AGED; NEURONS; PLATELET ACTIVATION; RECEPTOR, EPIDERMAL GROWTH FACTOR; YOUNG ADULT;

EID: 84920584352     PISSN: None     EISSN: 20414889     Source Type: Journal    
DOI: 10.1038/cddis.2014.373     Document Type: Article

References (62)

1. Wijten P, van Holten T, Woo LL, Bleijerveld OB, Roest M, Heck AJ et al. High precision platelet releasate definition by quantitative reversed protein profiling-brief report. Arterioscler Thromb Vasc Biol 2013; 33: 1635-1638.
2. Liu Y, Gao XM, Fang L, Jennings NL, Su Y, et al. Novel role of platelets in mediating inflammatory responses and ventricular rupture or remodeling following myocardial infarction. Arterioscler Thromb Vasc Biol 2011; 31: 834-841.
3. Nurden AT. Platelets, inflammation and tissue regeneration. Thromb Haemost 2011; 105(Suppl 1): S13-S33.
4. Bertozzi CC, Schmaier AA, Mericko P, Hess PR, Zou Z, Chen M et al. Platelets regulate lymphatic vascular development through CLEC-2-SLP-76 signaling. Blood 2010; 116: 661-670.
5. Erpenbeck L, Schon MP. Deadly allies: the fatal interplay between platelets and metastasizing cancer cells. Blood 2010; 115: 3427-3436.
6. Bambace NM, Holmes CE. The platelet contribution to cancer progression. J Thromb Haemost 2011; 9: 237-249.
7. Radziwon-Balicka A, Medina C, O'Driscoll L, Treumann A, Bazou D, Inkielewicz-Stepniak I et al. Platelets increase survival of adenocarcinoma cells challenged with anticancer drugs: mechanisms and implications for chemoresistance. Br J Pharmacol 2012; 167: 787-804.
8. Gentile P, Bottini DJ, Spallone D, Curcio BC, Cervelli V. Application of platelet-rich plasma in maxillofacial surgery: clinical evaluation. J Craniofac Surg 2010; 21: 900-904.
9. Rozman P, Bolta Z. Use of platelet growth factors in treating wounds and soft-tissue injuries. Acta Dermatovenerol Alp Panonica Adriat 2007; 16: 156-165.
10. Cervelli V, Lucarini L, Spallone D, Brinci L, de Angelis B. Use of platelet rich plasma and hyaluronic acid on exposed tendons of the foot and ankle 2010J Wound Care 19: 186, 188-190.
11. Hernandez E, Lavine M, Dunton CJ, Gracely E, Parker J. Poor prognosis associated with thrombocytosis in patients with cervical cancer. Cancer 1992; 69: 2975-2977.
12. Shimada H, Oohira G, Okazumi S, Matsubara H, Nabeya Y, Hayashi H et al. Thrombocytosis associated with poor prognosis in patients with esophageal carcinoma. J Am Coll Surg 2004; 198: 737-741.
13. Ikeda M, Furukawa H, Imamura H, Shimizu J, Ishida H, Masutani S et al. Poor prognosis associated with thrombocytosis in patients with gastric cancer. Ann Surg Oncol 2002; 9: 287-291.
14. Taucher S, Salat A, Gnant M, Kwasny W, Mlineritsch B, Menzel RC et al. Impact of pretreatment thrombocytosis on survival in primary breast cancer. Thromb Haemost 2003; 89: 1098-1106.
15. Al-Tamimi M, Grigoriadis G, Tran H, Paul E, Servadei P, Berndt MC et al. Coagulationinduced shedding of platelet glycoprotein VI mediated by factor Xa. Blood 2011; 117: 3912-3920.
16. Montecucco A, Biamonti G. Cellular response to etoposide treatment. Cancer Lett 2007; 252: 9-18.
17. Suh J, Lee YA, Gwag BJ. Induction and attenuation of neuronal apoptosis by proteasome inhibitors in murine cortical cell cultures. J Neurochem 2005; 95: 684-694.
18. Concannon CG, Koehler BF, Reimertz C, Murphy BM, Bonner C, Thurow N et al. Apoptosis induced by proteasome inhibition in cancer cells: predominant role of the p53/PUMA pathway. Oncogene 2007; 26: 1681-1692.
19. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005; 5: 363-372.
20. Polo SE, Jackson SP. Dynamics of DNA damage response proteins at DNA breaks: a focus on protein modifications. Genes Dev 2011; 25: 409-433.
21. Kong X, Shen Y, Jiang N, Fei X, Mi J. Emerging roles of DNA-PK besides DNA repair. Cell Signal 2011; 23: 1273-1280.
22. Culmsee C, Bondada S, Mattson MP. Hippocampal neurons of mice deficient in DNA-dependent protein kinase exhibit increased vulnerability to DNA damage, oxidative stress and excitotoxicity. Brain Res Mol Brain Res 2001; 87: 257-262.
23. Liccardi G, Hartley JA, Hochhauser D. EGFR nuclear translocation modulates DNA repair following cisplatin and ionizing radiation treatment. Cancer Res 2011; 71: 1103-1114.
24. Bandyopadhyay D, Mandal M, Adam L, Mendelsohn J, Kumar R. Physical interaction between epidermal growth factor receptor and DNA-dependent protein kinase in mammalian cells. J Biol Chem 1998; 273: 1568-1573.
25. Eccles SA. The epidermal growth factor receptor/Erb-B/HER family in normal and malignant breast biology. Int J Dev Biol 2011; 55: 685-696.
26. D'Incecco A, Cappuzzo F. Gefitinib for non-small-cell lung cancer treatment. Expert Opin Drug Saf 2011; 10: 987-996.
27. Muto T, Kokubu T, Mifune Y, Sakata R, Nagura I, Nishimoto H et al. Platelet-rich plasma protects rotator cuff-derived cells from the deleterious effects of triamcinolone acetonide. J Orthop Res 2013; 31: 976-982.
28. Fukaya Y, Kuroda M, Aoyagi Y, Asada S, Kubota Y, Okamoto Y et al. Platelet-rich plasma inhibits the apoptosis of highly adipogenic homogeneous preadipocytes in an in vitro culture system. Exp Mol Med 2012; 44: 330-339.
29. Song Q, Lees-Miller SP, Kumar S, Zhang Z, Chan DW, Smith GC et al. DNA-dependent protein kinase catalytic subunit: a target for an ICE-like protease in apoptosis. EMBO J 1996; 15: 3238-3246.
30. Sotnikov I, Veremeyko T, Starossom SC, Barteneva N, Weiner HL, Ponomarev ED. Platelets recognize brain-specific glycolipid structures, respond to neurovascular damage and promote neuroinflammation. PLoS One 2013; 8: e58979.
31. Thornton P, McColl BW, Greenhalgh A, Denes A, Allan SM, Rothwell NJ. Platelet interleukin-1alpha drives cerebrovascular inflammation. Blood 2010; 115: 3632-3639.
32. Joseph R, Tsering C, Grunfeld S, Welch KM. Platelet secretory products may contribute to neuronal injury. Stroke 1991; 22: 1448-1451.
33. Joseph R, Saroff DM, Delfs JR. Platelet secretory products have a damaging effect on neurons. Neurosci Lett 1992; 135: 153-158.
34. Hayon Y, Dashevsky O, Shai E, Varon D, Leker RR. Platelet lysates stimulate angiogenesis, neurogenesis and neuroprotection after stroke. Thromb Haemost 2013; 110: 323-330.
35. Jin K, Sun Y, Xie L, Childs J, Mao XO, Greenberg DA. Post-ischemic administration of heparin-binding epidermal growth factor-like growth factor (HB-EGF) reduces infarct size and modifies neurogenesis after focal cerebral ischemia in the rat. J Cereb Blood Flow Metab 2004; 24: 399-408.
36. Justicia C, Planas AM. Transforming growth factor-alpha acting at the epidermal growth factor receptor reduces infarct volume after permanent middle cerebral artery occlusion in rats. J Cereb Blood Flow Metab 1999; 19: 128-132.
37. Opanashuk LA, Mark RJ, Porter J, Damm D, Mattson MP, Seroogy KB. Heparin-binding epidermal growth factor-like growth factor in hippocampus: modulation of expression by seizures and anti-excitotoxic action. J Neurosci 1999; 19: 133-146.
38. Scafidi J, Hammond TR, Scafidi S, Ritter J, Jablonska B, Roncal M et al. Intranasal epidermal growth factor treatment rescues neonatal brain injury. Nature 2013; 506: 230-234.
39. Sun D, Bullock MR, Altememi N, Zhou Z, Hagood S, Rolfe A et al. The effect of epidermal growth factor in the injured brain after trauma in rats. J Neurotrauma 2010; 27: 923-938.
40. Neema M, Navarro-Quiroga I, Chechlacz M, Gilliams-Francis K, Liu J, Lamonica K et al. DNA damage and nonhomologous end joining in excitotoxicity: neuroprotective role of DNA-PKcs in kainic acid-induced seizures. Hippocampus 2005; 15: 1057-1071.
41. Nieswandt B, Hafner M, Echtenacher B, Mannel DN. Lysis of tumor cells by natural killer cells in mice is impeded by platelets. Cancer Res 1999; 59: 1295-1300.
42. Kunita A, Kashima TG, Ohazama A, Grigoriadis AE, Fukayama M. Podoplanin is regulated by AP-1 and promotes platelet aggregation and cell migration in osteosarcoma. Am J Pathol 2011; 179: 1041-1049.
43. Alonso-Escolano D, Medina C, Cieslik K, Radomski A, Jurasz P, Santos-Martinez MJ et al. Protein kinase C delta mediates platelet-induced breast cancer cell invasion. J Pharmacol Exp Ther 2006; 318: 373-380.
44. Boucharaba A, Serre CM, Gres S, Saulnier-Blache JS, Bordet JC, Guglielmi J et al. Platelet-derived lysophosphatidic acid supports the progression of osteolytic bone metastases in breast cancer. J Clin Invest 2004; 114: 1714-1725.
45. Pinedo HM, Verheul HM, D'Amato RJ, Folkman J. Involvement of platelets in tumour angiogenesis? Lancet 1998; 352: 1775-1777.
46. Feng W, Madajka M, Kerr BA, Mahabeleshwar GH, Whiteheart SW, Byzova TV. A novel role for platelet secretion in angiogenesis: mediating bone marrow-derived cell mobilization and homing. Blood 2011; 117: 3893-3902.
47. Rodriguez GC, Clarke-Pearson DL, Soper JT, Berchuck A, Synan I, Dodge RK. The negative prognostic implications of thrombocytosis in women with stage IB cervical cancer. Obstet Gynecol 1994; 83: 445-448.
48. Gonzalez Barcala FJ, Garcia Prim JM, Moldes Rodriguez M, Alvarez Fernandez J, Rey Rey MJ, Pose Reino A et al. Platelet count: association with prognosis in lung cancer. Med Oncol 2010; 27: 357-362.
49. Mukherjee B,McEllin B, Camacho CV, Tomimatsu N, Sirasanagandala S, Nannepaga S et al. EGFRvIII and DNA double-strand break repair: a molecular mechanism for radioresistance in glioblastoma. Cancer Res 2009; 69: 4252-4259.
50. Dittmann K, Mayer C, Rodemann HP. Inhibition of radiation-induced EGFR nuclear import by C225 (Cetuximab) suppresses DNA-PK activity. Radiother Oncol 2005; 76: 157-161.
51. Ciszewski WM, Tavecchio M, Dastych J, Curtin NJ. DNA-PK inhibition by NU7441 sensitizes breast cancer cells to ionizing radiation and doxorubicin. Breast Cancer Res Treat 2014; 143: 47-55.
52. Javvadi P, Makino H, Das AK, Lin YF, Chen DJ, Chen BP et al. Threonine 2609 phosphorylation of the DNA-dependent protein kinase is a critical prerequisite for epidermal growth factor receptor-mediated radiation resistance. Mol Cancer Res 2012; 10: 1359-1368.
53. Kang KB, Zhu C, Wong YL, Gao Q, Ty A, Wong MC. Gefitinib radiosensitizes stem-like glioma cells: inhibition of epidermal growth factor receptor-Akt-DNA-PK signaling, accompanied by inhibition of DNA double-strand break repair. Int J Radiat Oncol Biol Phys 2012; 83: e43-e52.
54. Dhomen NS, Mariadason J, Tebbutt N, Scott AM. Therapeutic targeting of the epidermal growth factor receptor in human cancer. Crit Rev Oncog 2012; 17: 31-50.
55. Pao W, Chmielecki J. Rational, biologically based treatment of EGFR-mutant non-smallcell lung cancer. Nat Rev Cancer 2010; 10: 760-774.
56. Troiani T, Martinelli E, Capasso A, Morgillo F, Orditura M, De Vita F et al. Targeting EGFR in pancreatic cancer treatment. Curr Drug Targets 2012; 13: 802-810.
57. Salles B, Calsou P, Frit P, Muller C. The DNA repair complex DNA-PK, a pharmacological target in cancer chemotherapy and radiotherapy. Pathol Biol 2006; 54: 185-193.
58. Al-Tamimi M, Mu FT, Moroi M, Gardiner EE, Berndt MC, Andrews RK. Measuring soluble platelet glycoprotein VI in human plasma by ELISA. Platelets 2009; 20: 143-149.
59. Samson AL, Knaupp AS, Sashindranath M, Borg RJ, Au AE, Cops EJ et al. Nucleocytoplasmic coagulation: an injury-induced aggregation event that disulfide crosslinks proteins and facilitates their removal by plasmin. Cell Rep 2012; 2: 889-901.
60. Kulkarni S, Woollard KJ, Thomas S, Oxley D, Jackson SP. Conversion of platelets from a proaggregatory to a proinflammatory adhesive phenotype: role of PAF in spatially regulating neutrophil adhesion and spreading. Blood 2007; 110: 1879-1886.
61. Craig R, Beavis RC. TANDEM: matching proteins with tandem mass spectra. Bioinformatics 2004; 20: 1466-1467.
62. Kessner D, Chambers M, Burke R, Agus D, Mallick P. ProteoWizard: open source software for rapid proteomics tools development. Bioinformatics 2008; 24: 2534-2536.